Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of eribulin (Halaven™) and cyclophosphamide
(Cytoxan®) given together at different doses. This study will look at what effects, good
and/or bad, that these drugs have on solid tumors. Eribulin is a drug that has been approved
by the FDA for breast cancer that has spread to other parts of the body. Cyclophosphamide has
been approved for different types of cancers (including breast cancer). However, the
combination of eribulin and cyclophosphamide is considered experimental; that means this
combination has not been approved by the FDA.
The funding for this study is provided by Eisai Inc., the maker of eribulin.